1.
Lancet
; 354(9188): 1441-2, 1999 Oct 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-10543673
RESUMO
Prospective follow-up of 136 babies exposed to ecstasy in utero indicated that the drug may be associated with a significantly increased risk of congenital defects (15.4% [95% CI 8.2-25.4]). Cardiovascular anomalies (26 per 1000 livebirths [3.0-90.0]) and musculoskeletal anomalies (38 per 1000 [8.0-109.0]) were predominant.